251 related articles for article (PubMed ID: 22457633)
1. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon.
Armitage AE; Deforche K; Chang CH; Wee E; Kramer B; Welch JJ; Gerstoft J; Fugger L; McMichael A; Rambaut A; Iversen AK
PLoS Genet; 2012; 8(3):e1002550. PubMed ID: 22457633
[TBL] [Abstract][Full Text] [Related]
2. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
[TBL] [Abstract][Full Text] [Related]
3. Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.
Armitage AE; Katzourakis A; de Oliveira T; Welch JJ; Belshaw R; Bishop KN; Kramer B; McMichael AJ; Rambaut A; Iversen AK
J Virol; 2008 Sep; 82(17):8743-61. PubMed ID: 18562517
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of the two cytidine deaminase domains in APOBEC3G.
Li X; Ma J; Zhang Q; Zhou J; Yin X; Zhai C; You X; Yu L; Guo F; Zhao L; Li Z; Zeng Y; Cen S
Virology; 2011 Jun; 414(2):130-6. PubMed ID: 21489586
[TBL] [Abstract][Full Text] [Related]
5. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G.
Cen S; Peng ZG; Li XY; Li ZR; Ma J; Wang YM; Fan B; You XF; Wang YP; Liu F; Shao RG; Zhao LX; Yu L; Jiang JD
J Biol Chem; 2010 May; 285(22):16546-52. PubMed ID: 20363737
[TBL] [Abstract][Full Text] [Related]
6. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
7. The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals.
Ulenga NK; Sarr AD; Hamel D; Sankale JL; Mboup S; Kanki PJ
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1285-90. PubMed ID: 18851679
[TBL] [Abstract][Full Text] [Related]
8. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G.
Miller JH; Presnyak V; Smith HC
Retrovirology; 2007 Nov; 4():81. PubMed ID: 18036235
[TBL] [Abstract][Full Text] [Related]
9. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.
Zhang L; Saadatmand J; Li X; Guo F; Niu M; Jiang J; Kleiman L; Cen S
Virology; 2008 Jan; 370(1):113-21. PubMed ID: 17916373
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
[TBL] [Abstract][Full Text] [Related]
11. Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding.
Bennett RP; Presnyak V; Wedekind JE; Smith HC
J Biol Chem; 2008 Mar; 283(12):7320-7. PubMed ID: 18165230
[TBL] [Abstract][Full Text] [Related]
12. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
14. Long-term passage of Vif-null HIV-1 in CD4
Miyagi E; Kao S; Fumitaka M; Buckler-White A; Plishka R; Strebel K
Virology; 2017 Apr; 504():1-11. PubMed ID: 28131088
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3G: a double agent in defense.
Smith HC
Trends Biochem Sci; 2011 May; 36(5):239-44. PubMed ID: 21239176
[TBL] [Abstract][Full Text] [Related]
16. Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy.
Hosseini I; Mac Gabhann F
PLoS Comput Biol; 2012 Feb; 8(2):e1002371. PubMed ID: 22346743
[TBL] [Abstract][Full Text] [Related]
17. Identification of small molecule compounds targeting the interaction of HIV-1 Vif and human APOBEC3G by virtual screening and biological evaluation.
Ma L; Zhang Z; Liu Z; Pan Q; Wang J; Li X; Guo F; Liang C; Hu L; Zhou J; Cen S
Sci Rep; 2018 May; 8(1):8067. PubMed ID: 29795228
[TBL] [Abstract][Full Text] [Related]
18. Mutation Vif-22H, which allows HIV-1 to use the APOBEC3G hypermutation to develop resistance, could appear more quickly in certain non-B variants.
Yebra G; Holguín A
J Antimicrob Chemother; 2011 Apr; 66(4):941-2. PubMed ID: 21393191
[No Abstract] [Full Text] [Related]
19. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
Pace C; Keller J; Nolan D; James I; Gaudieri S; Moore C; Mallal S
J Virol; 2006 Sep; 80(18):9259-69. PubMed ID: 16940537
[TBL] [Abstract][Full Text] [Related]
20. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
